Abstract
Adenosine-induced tachycardia is suggested to be mediated via A2A receptors; however, the exact mechanism for this effect remains to be understood. The present study was carried out using regadenoson, a selective A2A adenosine receptor agonist, to determine the role of the A2A receptor subtype in adenosine-induced tachycardia. Regadenoson (0.3-50 μg/kg) given as a rapid i.v. bolus to awake rats caused a dose-dependent increase in heart rate (HR). Mean arterial pressure (MAP) increased at lower doses, whereas at higher doses, there was a decrease in MAP. The increase in HR was evident at the lowest dose (0.3 μg/kg) of regadenoson at which there was no appreciable decrease in MAP. Pretreatment with 30 μg/kg ZM 241385 [4-(2-[7-amino-2-(2-furyl)-[1,2,4]-triazolo-[2,3-a]-[1,3,5]-triazin-5-ylamino]ethyl)phenol], an A2A receptor antagonist, attenuated the decrease in MAP and the increase in HR caused by regadenoson. Pretreatment with metoprolol (1 mg/kg), a β-blocker, attenuated the increase in HR but had no effect on the hypotension caused by regadenoson. In the presence of hexamethonium (10 mg/kg), a ganglionic blocker, the tachycardia was completely prevented even though MAP was further reduced. Regadenoson treatment (10 μg/kg) significantly (p < 0.05) increased plasma norepinephrine levels almost 2-fold above baseline. The dissociation of HR and MAP effects by dose, time, and pharmacological interventions provides evidence that tachycardia caused by regadenoson is independent of the decrease in MAP and may not entirely be baroreflex-mediated, suggesting that regadenoson may cause a direct stimulation of the sympathetic nervous system via activation of A2A adenosine receptors.
Footnotes
-
doi:10.1124/jpet.105.095323.
-
ABBREVIATIONS: regadenoson/CVT-3146, adenosine, 2-[4-(methylamino)carbonyl]-1H-pyrazol-1-yl]; ZM 241385, 4-(2-[7-amino-2-(2-furyl)-[1,2,4]-triazolo-[2,3-a]-[1,3,5]-triazin-5-ylamino]ethyl)phenol; CGS 21680, 2-p-(2-carboxyethyl)phenethylamino-5′-N-ethylcarboxamidoadenosine; NECA, 5′-N-ethylcarboxamido-adenosine; SNS, sympathetic nervous system; SNP, sodium nitroprusside; MAP, mean arterial pressure; MET, metoprolol; HEX, hexamethonium; ANOVA, analysis of variance; NE, norepinephrine.
- Received September 8, 2005.
- Accepted October 13, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|